Abstract
Oculopharyngeal muscular dystrophy (OPMD) is a rare, late-onset, autosomal-dominant disease affecting 1:100,000 individuals in Europe. OPMD is due to mutation in the N-terminal domain of exon 1 of the polyA-binding protein nuclear 1 (PABPN1). Patients with the disease express an expanded PABPN1 (expPABPN1) ranging from 11 to 18 alanines instead of the normal 10. OPMD is mainly characterized by ptosis and dysphagia, although muscles of the lower limbs can also be affected late in life. Currently, OPMD patients are referred to surgeons for a cricopharyngeal myotomy or corrective surgery to extraocular muscles to ease ptosis. Pharmacological treatments are not commercially available, but several compounds are in preclinical and clinical stages of development. A gene therapy approach designed to inhibit the expression of expPABPN1 is an appealing strategy. However, due to the type of mutation, genetic strategies to knock down expPABPN1 invariably affect the expression of wild-type PABPN1 with potential negative consequences for the treated muscles. We recently demonstrated that a dual gene therapy approach designed to inhibit mutant and wild-type endogenous PABPN1 by shRNA, in combination with expression of an RNAi-resistant sequence-optimized recombinant PABPN1 gene, substantially rescues the pathology in the A17 mouse model of OPMD. This is currently the only preclinical gene therapy study for OPMD. In this chapter, we describe this approach in a general context of other possible treatments for OPMD, and we discuss the likely future developments that may allow the translation of such an approach towards a therapeutic treatment for OPMD in humans.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Vita G, Dattola R, Santoro M, Messina C (1983) Familial oculopharyngeal muscular dystrophy with distal spread. J Neurol 230(1):57–64
Lim CT, Chew CT, Chew SH (1992) Oculopharyngeal muscular dystrophy: a case report and a review of literature. Ann Acad Med Singap 21(3):399–403
Uyama E, Nohira O, Tome FM, Chateau D, Tokunaga M, Ando M, Maki M, Okabe T, Uchino M (1997) Oculopharyngeal muscular dystrophy in Japan. Neuromuscul Disord 7(Suppl 1):S41–S49
Uyama E, Nohira O, Chateau D, Tokunaga M, Uchino M, Okabe T, Ando M, Tome FM (1996) Oculopharyngeal muscular dystrophy in two unrelated Japanese families. Neurology 46(3):773–778
Teh BT, Sullivan AA, Farnebo F, Zander C, Li FY, Strachan N, Schalling M, Larsson C, Sandstrom P (1997) Oculopharyngeal muscular dystrophy (OPMD)--report and genetic studies of an Australian kindred. Clin Genet 51(1):52–55
Fardeau M, Tome FM (1997) Oculopharyngeal muscular dystrophy in France. Neuromuscul Disord 7(Suppl 1):S30–S33
Blumen SC, Nisipeanu P, Sadeh M, Asherov A, Blumen N, Wirguin Y, Khilkevich O, Carasso RL, Korczyn AD (1997) Epidemiology and inheritance of oculopharyngeal muscular dystrophy in Israel. Neuromuscul Disord 7(Suppl 1):S38–S40
Medici M, Pizzarossa C, Skuk D, Yorio D, Emmanuelli G, Mesa R (1997) Oculopharyngeal muscular dystrophy in Uruguay. Neuromuscul Disord 7(Suppl 1):S50–S52
Meola G, Sansone V, Rotondo G, Tome FM, Bouchard JP (1997) Oculopharyngeal muscular dystrophy in Italy. Neuromuscul Disord 7(Suppl 1):S53–S56
Porschke H, Kress W, Reichmann H, Goebel HH, Grimm T (1997) Oculopharyngeal muscular dystrophy in a northern German family linked to chromosome 14q, and presenting carnitine deficiency. Neuromuscul Disord 7(Suppl 1):S57–S62
Grewal RP, Karkera JD, Grewal RK, Detera-Wadleigh SD (1999) Mutation analysis of oculopharyngeal muscular dystrophy in Hispanic American families. Arch Neurol 56(11):1378–1381
Becher MW, Morrison L, Davis LE, Maki WC, King MK, Bicknell JM, Reinert BL, Bartolo C, Bear DG (2001) Oculopharyngeal muscular dystrophy in Hispanic New Mexicans. JAMA 286(19):2437–2440. https://doi.org/10.1001/jama.286.19.2437
Brais B, Xie YG, Sanson M, Morgan K, Weissenbach J, Korczyn AD, Blumen SC, Fardeau M, Tome FM, Bouchard JP et al (1995) The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13. Hum Mol Genet 4(3):429–434
Tome F, Fardeau M (1994) Oculopharyngeal muscular dystrophy. In: Engel AG, Franzini-Armstrong C (eds) Myology, vol 2. McGraw-Hil, New York, pp 1233–1245
Blumen SC, Nisipeanu P, Sadeh M, Asherov A, Tome FM, Korczyn AD (1993) Clinical features of oculopharyngeal muscular dystrophy among Bukhara Jews. Neuromuscul Disord 3(5–6):575–577
Barbeau A (1966) Ocular myopathy in French Canada. A preliminary study. J Genet Hum 15(Suppl):49–55
Probst A, Tackmann W, Stoeckli HR, Jerusalem F, Ulrich J (1982) Evidence for a chronic axonal atrophy in oculopharyngeal “muscular dystrophy”. Acta Neuropathol 57(2–3):209–216
Schober R, Kress W, Grahmann F, Kellermann S, Baum P, Gunzel S, Wagner A (2001) Unusual triplet expansion associated with neurogenic changes in a family with oculopharyngeal muscular dystrophy. Neuropathology 21(1):45–52
Dubbioso R, Moretta P, Manganelli F, Fiorillo C, Iodice R, Trojano L, Santoro L (2012) Executive functions are impaired in heterozygote patients with oculopharyngeal muscular dystrophy. J Neurol 259(5):833–837. https://doi.org/10.1007/s00415-011-6255-y
Linoli G, Tomelleri G, Ghezzi M (1991) Oculopharyngeal muscular dystrophy. Description of a case with involvement of the central nervous system. Pathologica 83(1085):325–334
Brais B, Bouchard JP, Xie YG, Rochefort DL, Chretien N, Tome FM, Lafreniere RG, Rommens JM, Uyama E, Nohira O, Blumen S, Korczyn AD, Heutink P, Mathieu J, Duranceau A, Codere F, Fardeau M, Rouleau GA (1998) Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 18(2):164–167
Jouan L, Rocheford D, Szuto A, Carney E, David K, Dion PA, Rouleau GA (2014) An 18 alanine repeat in a severe form of oculopharyngeal muscular dystrophy. Can J Neurol Sci 41(4):508–511
Richard P, Trollet C, Stoijkovic T, De Becdelievre A, Perie S, Pouget J, Eymard B, neurologists CF (2017) Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy. Neurology 88(4):359–365. https://doi.org/10.1212/WNL.0000000000003554
Blumen SC, Brais B, Korczyn AD, Medinsky S, Chapman J, Asherov A, Nisipeanu P, Codere F, Bouchard JP, Fardeau M, Tome FM, Rouleau GA (1999) Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease. Ann Neurol 46(1):115–118
Tondo M, Gamez J, Gutierrez-Rivas E, Medel-Jimenez R, Martorell L (2012) Genotype and phenotype study of 34 Spanish patients diagnosed with oculopharyngeal muscular dystrophy. J Neurol 259(8):1546–1552. https://doi.org/10.1007/s00415-011-6374-5
Shan J, Chen B, Lin P, Li D, Luo Y, Ji K, Zheng J, Yuan Y, Yan C (2014) Oculopharyngeal muscular dystrophy: phenotypic and genotypic studies in a Chinese population. NeuroMolecular Med 16(4):782–786. https://doi.org/10.1007/s12017-014-8327-5
Robinson DO, Hammans SR, Read SP, Sillibourne J (2005) Oculopharyngeal muscular dystrophy (OPMD): analysis of the PABPN1 gene expansion sequence in 86 patients reveals 13 different expansion types and further evidence for unequal recombination as the mutational mechanism. Hum Genet 116(4):267–271. https://doi.org/10.1007/s00439-004-1235-2
Muller T, Deschauer M, Kolbe-Fehr F, Zierz S (2006) Genetic heterogeneity in 30 German patients with oculopharyngeal muscular dystrophy. J Neurol 253(7):892–895. https://doi.org/10.1007/s00415-006-0126-y
Mirabella M, Silvestri G, de Rosa G, Di Giovanni S, Di Muzio A, Uncini A, Tonali P, Servidei S (2000) GCG genetic expansions in Italian patients with oculopharyngeal muscular dystrophy. Neurology 54(3):608–614
Hill ME, Creed GA, McMullan TF, Tyers AG, Hilton-Jones D, Robinson DO, Hammans SR (2001) Oculopharyngeal muscular dystrophy: phenotypic and genotypic studies in a UK population. Brain 124(Pt 3):522–526
Agarwal PK, Mansfield DC, Mechan D, Al-Shahi Salman R, Davenport RJ, Connor M, Metcalfe R, Petty R (2011) Delayed diagnosis of oculopharyngeal muscular dystrophy in Scotland. Br J Ophthalmol 96(2):281–283. https://doi.org/10.1136/bjo.2010.200378
Banerjee A, Apponi LH, Pavlath GK, Corbett AH (2013) PABPN1: molecular function and muscle disease. FEBS J 280(17):4230–4250. https://doi.org/10.1111/febs.12294
Eckmann CR, Rammelt C, Wahle E (2011) Control of poly(A) tail length. Wiley Interdiscip Rev RNA 2(3):348–361. https://doi.org/10.1002/wrna.56
Apponi LH, Leung SW, Williams KR, Valentini SR, Corbett AH, Pavlath GK (2009) Loss of nuclear poly(A)-binding protein 1 (PABPN1) causes defects in myogenesis and mRNA biogenesis. Hum Mol Genet 19(6):1058–1065. https://doi.org/10.1093/hmg/ddp569
Benoit B, Mitou G, Chartier A, Temme C, Zaessinger S, Wahle E, Busseau I, Simonelig M (2005) An essential cytoplasmic function for the nuclear poly(A) binding protein, PABP2, in poly(A) tail length control and early development in Drosophila. Dev Cell 9(4):511–522
Nguyen D, Grenier St-Sauveur V, Bergeron D, Dupuis-Sandoval F, Scott MS, Bachand F (2015) A polyadenylation-dependent 3′ end maturation pathway is required for the synthesis of the human telomerase RNA. Cell Rep 13(10):2244–2257. https://doi.org/10.1016/j.celrep.2015.11.003
de Klerk E, Venema A, Anvar SY, Goeman JJ, Hu O, Trollet C, Dickson G, den Dunnen JT, van der Maarel SM, Raz V, t Hoen PA (2012) Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation. Nucleic acids res 40(18):9089–9101. https://doi.org/10.1093/nar/gks655
Jenal M, Elkon R, Loayza-Puch F, van Haaften G, Kuhn U, Menzies FM, Vrielink JA, Bos AJ, Drost J, Rooijers K, Rubinsztein DC, Agami R (2012) The poly(a)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. Cell 149(3):538–553. https://doi.org/10.1016/j.cell.2012.03.022
Beaulieu YB, Kleinman CL, Landry-Voyer AM, Majewski J, Bachand F (2012) Polyadenylation-dependent control of long noncoding RNA expression by the poly(A)-binding protein nuclear 1. PLoS Genet 8(11):e1003078. https://doi.org/10.1371/journal.pgen.1003078
Lemay JF, D’Amours A, Lemieux C, Lackner DH, St-Sauveur VG, Bahler J, Bachand F (2010) The nuclear poly(A)-binding protein interacts with the exosome to promote synthesis of noncoding small nucleolar RNAs. Mol Cell 37(1):34–45. https://doi.org/10.1016/j.molcel.2009.12.019
Bresson SM, Conrad NK (2013) The human nuclear poly(a)-binding protein promotes RNA hyperadenylation and decay. PLoS Genet 9(10):e1003893. https://doi.org/10.1371/journal.pgen.1003893
Bergeron D, Pal G, Beaulieu YB, Chabot B, Bachand F (2015) Regulated intron retention and nuclear pre-mRNA decay contribute to PABPN1 autoregulation. Mol Cell Biol 35(14):2503–2517. https://doi.org/10.1128/MCB.00070-15
Muniz L, Davidson L, West S (2015) Poly(A) polymerase and the nuclear poly(A) binding protein, PABPN1, coordinate the splicing and degradation of a subset of human pre-mRNAs. Mol Cell Biol 35(13):2218–2230. https://doi.org/10.1128/MCB.00123-15
Calado A, Tome FM, Brais B, Rouleau GA, Kuhn U, Wahle E, Carmo-Fonseca M (2000) Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum Mol Genet 9(15):2321–2328
Chartier A, Klein P, Pierson S, Barbezier N, Gidaro T, Casas F, Carberry S, Dowling P, Maynadier L, Bellec M, Oloko M, Jardel C, Moritz B, Dickson G, Mouly V, Ohlendieck K, Butler-Browne G, Trollet C, Simonelig M (2015) Mitochondrial dysfunction reveals the role of mRNA poly(A) tail regulation in oculopharyngeal muscular dystrophy pathogenesis. PLoS Genet 11(3):e1005092. https://doi.org/10.1371/journal.pgen.1005092
Gidaro T, Negroni E, Perie S, Mirabella M, Laine J, Lacau St Guily J, Butler-Browne G, Mouly V, Trollet C (2013) Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients. J Neuropathol Exp Neurol 72(3):234–243. https://doi.org/10.1097/NEN.0b013e3182854c07
Tome FM, Fardeau M (1980) Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathol 49(1):85–87
Winklhofer KF, Tatzelt J, Haass C (2008) The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J 27(2):336–349. https://doi.org/10.1038/sj.emboj.7601930
Eisele YS, Monteiro C, Fearns C, Encalada SE, Wiseman RL, Powers ET, Kelly JW (2015) Targeting protein aggregation for the treatment of degenerative diseases. Nat Rev Drug Discov 14(11):759–780. https://doi.org/10.1038/nrd4593
Becher MW, Kotzuk JA, Davis LE, Bear DG (2000) Intranuclear inclusions in oculopharyngeal muscular dystrophy contain poly(A) binding protein 2. Ann Neurol 48(5):812–815
Harish P, Malerba A, Dickson G, Bachtarzi H (2015) Progress on gene therapy, cell therapy, and pharmacological strategies toward the treatment of oculopharyngeal muscular dystrophy. Hum Gene Ther 26(5):286–292. https://doi.org/10.1089/hum.2015.014
Trollet C, Anvar SY, Venema A, Hargreaves IP, Foster K, Vignaud A, Ferry A, Negroni E, Hourde C, Baraibar MA, t Hoen PA, Davies JE, Rubinsztein DC, Heales SJ, Mouly V, van der Maarel SM, Butler-Browne G, Raz V, Dickson G (2010) Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres. Hum Mol Genet 19(11):2191–2207. https://doi.org/10.1093/hmg/ddq098
Corbeil-Girard LP, Klein AF, Sasseville AM, Lavoie H, Dicaire MJ, Saint-Denis A, Page M, Duranceau A, Codere F, Bouchard JP, Karpati G, Rouleau GA, Massie B, Langelier Y, Brais B (2005) PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions. Neurobiol Dis 18(3):551–567
Beard C (1978) Advancements in ptosis surgery. Clin Plast Surg 5(4):537–545
Collin JR (1988) New concepts in the management of ptosis. Eye 2(Pt 2):185–188. https://doi.org/10.1038/eye.1988.33
Rodrigue D, Molgat YM (1997) Surgical correction of blepharoptosis in oculopharyngeal muscular dystrophy. Neuromuscul Disord 7(Suppl 1):S82–S84
Trollet C, Gidaro T, Klein P, Perie S, Butler-Browne G, Lacau St Guily J (1993) Oculopharyngeal muscular dystrophy. ID: NBK1126 [bookaccession]
Manjaly JG, Vaughan-Shaw PG, Dale OT, Tyler S, Corlett JC, Frost RA (2012) Cricopharyngeal dilatation for the long-term treatment of dysphagia in oculopharyngeal muscular dystrophy. Dysphagia 27(2):216–220. https://doi.org/10.1007/s00455-011-9356-y
Perie S, Trollet C, Mouly V, Vanneaux V, Mamchaoui K, Bouazza B, Pierre Marolleau J, Laforet P, Chapon F, Eymard B, Butler-Browne G, Larghero J, St Guily JL (2013) Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a Phase I/IIa clinical study. Mol Ther. https://doi.org/10.1038/mt.2013.155
Argov Z, Gliko-Kabir I, Brais B, Caraco Y, Megiddo D (2016) Intravenous trehalose improves dysphagia and muscle function in oculopharyngeal muscular dystrophy (OPMD): preliminary results of 24 weeks open label phase 2. Trial Neurol 86(16 Suppl S28.004)
Bao YP, Cook LJ, O’Donovan D, Uyama E, Rubinsztein DC (2002) Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. J Biol Chem 277(14):12263–12269
Wang Q, Mosser DD, Bag J (2005) Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells. Hum Mol Genet 14(23):3673–3684
Barbezier N, Chartier A, Bidet Y, Buttstedt A, Voisset C, Galons H, Blondel M, Schwarz E, Simonelig M (2011) Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy. EMBO Mol Med 3(1):35–49. https://doi.org/10.1002/emmm.201000109
Ross CJ, Twisk J, Bakker AC, Miao F, Verbart D, Rip J, Godbey T, Dijkhuizen P, Hermens WT, Kastelein JJ, Kuivenhoven JA, Meulenberg JM, Hayden MR (2006) Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther 17(5):487–499. https://doi.org/10.1089/hum.2006.17.487
Spencer HT, Riley BE, Doering CB (2016) State of the art: gene therapy of haemophilia. Haemophilia 22(Suppl 5):66–71. https://doi.org/10.1111/hae.13011
DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, Yoder J, Reeves P, Pandey RK, Rajeev KG, Manoharan M, Sah DW, Zamore PD, Aronin N (2007) Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A 104(43):17204–17209. https://doi.org/10.1073/pnas.0708285104
Zimmermann TS, Karsten V, Chan A, Chiesa J, Boyce M, Bettencourt BR, Hutabarat R, Nochur S, Vaishnaw A, Gollob J (2017) Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate. Mol Ther 25(1):71–78. https://doi.org/10.1016/j.ymthe.2016.10.019
Suhy DA, Kao SC, Mao T, Whiteley L, Denise H, Souberbielle B, Burdick AD, Hayes K, Wright JF, Lavender H, Roelvink P, Kolykhalov A, Brady K, Moschos SA, Hauck B, Zelenaia O, Zhou S, Scribner C, High KA, Renison SH, Corbau R (2012) Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model. Mol Ther 20(9):1737–1749. https://doi.org/10.1038/mt.2012.119
Fan HC, Ho LI, Chi CS, Chen SJ, Peng GS, Chan TM, Lin SZ, Harn HJ (2014) Polyglutamine (PolyQ) diseases: genetics to treatments. Cell Transplant 23(4–5):441–458. https://doi.org/10.3727/096368914X678454
Harper SQ (2009) Progress and challenges in RNA interference therapy for Huntington disease. Arch Neurol 66(8):933–938. https://doi.org/10.1001/archneurol.2009.180
Capon SJ, Baillie GJ, Bower NI, da Silva JA, Paterson S, Hogan BM, Simons C, Smith KA (2017) Utilising polymorphisms to achieve allele-specific genome editing in zebrafish. Biol Open 6(1):125–131. https://doi.org/10.1242/bio.020974
Keiser MS, Kordasiewicz HB, McBride JL (2016) Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington’s disease and spinocerebellar ataxia. Hum Mol Genet 25(R1):R53–R64. https://doi.org/10.1093/hmg/ddv442
Farrar GJ, Millington-Ward S, Chadderton N, Humphries P, Kenna PF (2012) Gene-based therapies for dominantly inherited retinopathies. Gene Ther 19(2):137–144. https://doi.org/10.1038/gt.2011.172
Millington-Ward S, Chadderton N, O’Reilly M, Palfi A, Goldmann T, Kilty C, Humphries M, Wolfrum U, Bennett J, Humphries P, Kenna PF, Farrar GJ (2011) Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol Ther 19(4):642–649. https://doi.org/10.1038/mt.2010.293
Millington-Ward S, O’Neill B, Tuohy G, Al-Jandal N, Kiang AS, Kenna PF, Palfi A, Hayden P, Mansergh F, Kennan A, Humphries P, Farrar GJ (1997) Strategems in vitro for gene therapies directed to dominant mutations. Hum Mol Genet 6(9):1415–1426
Malerba A, Klein P, Bachtarzi H, Jarmin SA, Cordova G, Ferry A, Strings V, Polay Espinoza M, Mamchaoui K, Blumen SC, Lacau St Guily J, Mouly V, Graham M, Butler-Browne G, Suhy DA, Trollet C, Dickson G (2017) PABPN1 gene therapy for oculopharyngeal muscular dystrophy. Nat Commun 31(8):14848. https://doi.org/10.1038/ncomms14848
Davies JE, Wang L, Garcia-Oroz L, Cook LJ, Vacher C, O’Donovan DG, Rubinsztein DC (2005) Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med 11(6):672–677
McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, Gilmore BL, Burstein H, Peluso RW, Polisky B, Carter BJ, Davidson BL (2008) Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A 105(15):5868–5873
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Malerba, A. et al. (2019). Gene Therapy for Oculopharyngeal Muscular Dystrophy. In: Duan, D., Mendell, J. (eds) Muscle Gene Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-03095-7_31
Download citation
DOI: https://doi.org/10.1007/978-3-030-03095-7_31
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-03094-0
Online ISBN: 978-3-030-03095-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)